Recruiting OBSERVATIONAL NCT04743479

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI) (ESPRIT-AI)

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer

Sponsor: Changhai Hospital

Conditions Chronic Pancreatitis Diabetes Familial Pancreatic Cancer Hereditary Pancreatitis Pancreatic Cancer Pancreatic Cystic Neoplasm

Interventions high-resolution MRI/CT examinations

Updated 6 times since 2021 Last updated: Aug 31, 2023 Started: Dec 1, 2020 Primary completion: Dec 30, 2025 Completion: Dec 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04743479, this observational or N/A phase trial focuses on Chronic Pancreatitis and Diabetes and remains actively recruiting participants. Sponsored by Changhai Hospital, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Oct 2023 — Jul 2024 [monthly]

Recruiting
Apr 2022 — Oct 2023 [monthly]

Recruiting
Dec 2021 — Apr 2022 [monthly]

Recruiting

▶ Show 1 earlier version

Mar 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changhai Hospital

Data source: Changhai Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China